Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07217067 · ClinicalTrials.gov registry record · Phase 2

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

A Phase 2 study of Atrial Fibrillation, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
165
Enrollment target
20
Study locations

NCT07217067 is a Phase 2 study of Atrial Fibrillation that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 165 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07217067, a Phase 2 study of Atrial Fibrillation, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
165 participants
Enrollment target
20
Study locations

Study Summary

A randomized, placebo-controlled, participant-and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden as well as the safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation

Conditions Studied

Atrial Fibrillation

Interventions

  • OTHER Placebo
  • DRUG PKN605

Study Locations (20)

Other

  • Novartis Investigative Site - Xi'an
  • Novartis Investigative Site - Bad Homburg
  • Novartis Investigative Site - Berlin
  • Novartis Investigative Site - Berlin
  • Novartis Investigative Site - Hamburg
  • Novartis Investigative Site - Hamburg

Quebec

  • Novartis Investigative Site - Montreal
  • Novartis Investigative Site - Montreal
  • Novartis Investigative Site - Montreal
  • Novartis Investigative Site - Québec
  • Novartis Investigative Site - Sherbrooke

Ontario

  • Novartis Investigative Site - London
  • Novartis Investigative Site - Newmarket
  • Novartis Investigative Site - Toronto

Mississippi

  • Cardiology Associates of North MS - Tupelo

New York

  • Weill Cornell Medical Center - New York

Utah

  • Intermountain Medical Center - Murray

Washington

  • Swedish Heart and Vascular Clinic - Seattle

Beijing Municipality

  • Novartis Investigative Site - Beijing

Trial Details

FieldValue
Enrollment Target 165 participants
Start Date 2025-10-28
Est. Completion 2027-09-09
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07217067

The ClinicalTrials.gov registry entry for NCT07217067 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (94% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07217067 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Quebec, Ontario.

Frequently Asked Questions

What is clinical trial NCT07217067 about?

NCT07217067 is a clinical study titled "A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation". A randomized, placebo-controlled, participant-and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden as well as the safety, tolerability and pharmacokinetics of PKN605 in participants with atrial fibrillation

What is the current status of trial NCT07217067?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2025-10-28. Estimated completion is 2027-09-09.

What conditions does trial NCT07217067 study?

This clinical trial studies the following conditions: Atrial Fibrillation.

What interventions are being tested in trial NCT07217067?

The interventions under investigation include: Placebo (OTHER), PKN605 (DRUG).

Who is sponsoring clinical trial NCT07217067?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07217067 being conducted?

This trial has 20 study locations across Mississippi, New York, Utah, Washington, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atrial Fibrillation

All registered trials for this condition

Mississippi

All trials with a study site in Mississippi

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.